Multiple Dark Antigens

Multiple Dark Antigens represent a novel class of tumor-specific targets derived from the "dark genome," which comprises the approximately 98% of the human genome that does not encode traditional proteins [4, 7]. These antigens are generated from non-canonical genomic regions, such as introns, untranslated regions (UTRs), and transposable elements, which are typically silenced in healthy cells but become transcriptionally active in cancer due to epigenetic and translational dysregulation [10, 13]. In ovarian cancer, these antigens provide a rich source of shared, highly specific targets that can overcome the limitations of low mutational burden and the high cost of personalized neoantigen therapies [2, 15]. Therapeutic strategies targeting these antigens include off-the-shelf cancer vaccines and T-cell receptor (TCR)-based immunotherapies, such as those being developed by Enara Bio and its partners [5, 14]. A key example is the DARKFOX antigen, a validated dark antigen targeted by the bispecific T-cell engager ENA101, which is expressed across multiple solid tumors including ovarian cancer [8, 9]. By targeting multiple dark antigens simultaneously, these therapies aim to maximize population coverage and minimize the risk of tumor escape through antigen loss [3, 12]. This approach leverages the unique immunogenicity of non-canonical peptides presented on Human Leukocyte Antigen (HLA) molecules to induce potent T-cell-mediated anti-tumor responses [6, 11].

Other names

Dark AntigensNon-canonical antigensCryptic antigensHidden antigensEnara Dark AntigensEDAsGenomic dark matter antigens

Induction of T-cell mediated cytotoxicity against tumor cells presenting non-canonical peptides on MHC molecules.